Eli Lilly and Company announced Josh Bilenker (pictured), Nisha Nanda (pictured) and Jacob Van Naarden will jointly lead the company’s new organization, Loxo Oncology at Lilly.  All three serve in management at Loxo, which Lilly acquired in early 2019.

The company also announced that David Hyman will join the leadership team as chief medical officer of the new organization, beginning in January 2020. He currently serves as chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center.

The new organization will have an expanded global presence, with team members in Boulder, Colorado; Indianapolis, Indiana; New York City, New York; South San Francisco, California; Stamford, Connecticut; and Madrid, Spain.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}